Does pregabalin cause an increase in blood pressure, particularly at doses ≥300 mg per day or in patients with hypertension or on thiazolidinediones?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Does Pregabalin Cause Blood Pressure Elevation?

Yes, pregabalin can cause blood pressure increases, particularly at higher doses (≥300 mg/day), though the evidence is mixed and the effect appears modest in most patients.

Key Evidence from FDA Drug Label

The FDA-approved prescribing information does not list hypertension as a primary adverse effect of pregabalin 1. However, the label notes dose-dependent adverse reactions are common at doses above 300 mg/day, and specifically recommends against routine use of doses exceeding 300 mg/day for most indications due to increased adverse effects without additional efficacy 1.

Clinical Research Findings

Evidence Supporting Blood Pressure Effects:

Recent observational data suggests cardiovascular concerns with long-term use. A large retrospective cohort study of 210,064 patients with diabetic neuropathy found that pregabalin was associated with increased 5-year cardiovascular risk, including heart failure (HR: 1.2), myocardial infarction (HR: 1.29), and stroke (HR: 1.26) 2. While this study examined cardiovascular events rather than direct blood pressure measurements, the mechanism is hypothesized to involve fluid retention, which could contribute to blood pressure elevation 2.

Acute hypertension has been documented in toxicity cases. A case report described a patient who developed hypertension and tachycardia after ingesting 1000 mg of pregabalin, subsequently developing posterior reversible encephalopathy syndrome (PRES) 3. This represents an extreme scenario but demonstrates pregabalin's potential to acutely elevate blood pressure at supratherapeutic doses.

Animal studies show dose-dependent blood pressure reduction. Interestingly, a feline study found that pregabalin at 5 mg/kg and 10 mg/kg actually caused significant reductions in systolic blood pressure compared to placebo 4. This contradicts the human hypertension concern and may reflect species differences or dosing variations.

Evidence Against Significant Blood Pressure Effects:

Controlled human studies show minimal cardiovascular impact. A double-blind, placebo-controlled study comparing venlafaxine, pregabalin (200 mg/day), and placebo over 3 weeks found that pregabalin did not significantly raise blood pressure, heart rate, or affect orthostatic responses, whereas venlafaxine clearly did 5. This suggests pregabalin's cardiovascular profile differs substantially from medications known to cause hypertension.

Perioperative studies show blood pressure stabilization. A randomized controlled trial examining pregabalin (150 mg and 300 mg) before endotracheal intubation found that pregabalin actually reduced blood pressure fluctuations after intubation, with no significant difference between doses 6. This suggests pregabalin may have blood pressure-stabilizing rather than elevating effects in acute stress situations.

Clinical Context and Guidelines

Neuropathic pain guidelines do not highlight hypertension as a concern. The Mayo Clinic neuropathic pain management guidelines extensively discuss pregabalin dosing (150-600 mg/day) and adverse effects, noting dizziness and sedation as primary concerns, but do not mention blood pressure elevation 7. The guidelines emphasize that doses above 300 mg/day are associated with greater adverse effects without consistent additional benefit 7.

Hypertension guidelines do not list pregabalin as a blood pressure-elevating medication. Multiple comprehensive hypertension guidelines from 2010-2025, including those from the WHO, AHA/ACC, ESC, and Hypertension Canada, do not identify pregabalin among medications that cause drug-induced hypertension 8, 9, 10, 11, 12, 13, 14. A review of drug-induced hypertension similarly does not list pregabalin 15.

Clinical Recommendations

Monitor blood pressure in patients on pregabalin, particularly:

  • Those receiving doses ≥300 mg/day
  • Patients with pre-existing hypertension
  • Those with diabetic neuropathy (given the cardiovascular risk data)
  • Elderly patients or those with renal impairment (who require dose adjustment) 1

Practical approach:

  1. Start low, go slow: Begin at 150 mg/day and titrate based on efficacy and tolerability 1
  2. Avoid routine use above 300 mg/day unless patients have inadequate pain relief and tolerate lower doses well 1
  3. Monitor for fluid retention (peripheral edema), which may be the mechanism linking pregabalin to cardiovascular effects 2, 16
  4. Consider dose reduction in renal impairment, as pregabalin is renally cleared and accumulation may increase adverse effects 1

Important Caveats

The evidence is conflicting: acute controlled studies show no hypertensive effect or even blood pressure reduction 6, 5, while long-term observational data suggests increased cardiovascular risk 2. The mechanism remains unclear—fluid retention is hypothesized but not definitively proven. The cardiovascular risk may be confounded by the underlying conditions (diabetic neuropathy) rather than pregabalin itself.

The relationship between pregabalin and blood pressure elevation is not definitively established, but prudent monitoring is warranted, especially at higher doses and in vulnerable populations.

References

Related Questions

In a patient with intact foot sensation, normal pulses, negative foot exam, who stopped pregabalin (Lyrica) due to peripheral edema after partial pain relief, now has severe plantar pain unrelieved by PRN Lyrica, serum osmolality of 297 mOsm/kg, persistent thirst, weight loss, orthostatic hypotension in the morning and later‑day hypertension, what diagnostic work‑up and treatment plan should be pursued for possible endocrine dysfunction and neuropathic pain management?
How should I manage a patient who was prescribed 100 mg of pregabalin (Lyrica) but inadvertently received a 200 mg dose?
How do systemic anticholinergic drugs affect blood pressure, and what monitoring or precautions are recommended for patients with hypertension, cardiovascular disease, or the elderly?
In a patient taking exemestane who presents with new-onset hypertension, syncope with dizziness, and a motor vehicle accident, should the exemestane be held until the cardiovascular cause is evaluated?
What could cause a patient's blood pressure to fluctuate substantially from day to day despite consistent antihypertensive medication adherence and no significant changes in diet or sodium intake?
How should a blood ethanol concentration of 150 mg/dL be interpreted regarding intoxication severity and immediate clinical management?
Could heterotopic ossification of the leg be associated with sarcoidosis?
What are the recommended treatments for oral and vaginal candidiasis (thrush) in pregnant patients?
When should D5 1/2 NS (5% dextrose in 0.45% saline) be chosen over D5 NS (5% dextrose in 0.9% saline) for intravenous fluid therapy?
What is the recommended action if I miss a dose of fluvoxamine?
For peripheral intravenous (IV) access, is it permissible to use the same needle for a second insertion on the same patient if the needle remains sterile?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.